

Supplementary material

Supplementary table 1. Demographic features of study participants.

Characteristic	
Female, <i>n</i> (%)	284 (84.02)
Age, (years) (mean ± SD)	44.99±14.58
BMI, kg/m², (mean ± SD)	21.93±3.92
Smoker, <i>n</i> (%)	20 (5.92)
Type, <i>n</i> (%)	231 (68.14)
LE	107 (31.65)
RA	
Subgroup of LE, <i>n</i> (%)	119 (51.51)
Systematic LE	15 (6.49)
Lupus nephritis	14 (6.06)
Lupus pneumonitis	31 (13.44)
Lupus encephalitis	76 (32.90)
Blood system	7 (3.03)
Others	
Cutaneous LE	
Concomitant diseases, <i>n</i> (%)	259 (76.62)
Hypertension	78 (23.07)
Diabetes	16 (4.73)
Cardiovascular disease	19 (5.62)
Chronic pulmonary disease	46 (13.60)
Malignancy	4 (1.18)
Discontinuation of medication, <i>n</i> (%)	32 (9.46)
Discontinuation due to COVID-19	15 (4.43)
Discontinuation due to adverse effect	8 (2.37)
Discontinuation due to remission	8 (2.37)
Others	1 (0.29)
Clinical outcome, (%)	
Complete remission	138 (40.8)
Partial remission	149 (44.08)
Stable disease	14 (4.14)
Progressive disease	30 (8.87)
Death	7 (2.07)
Recent residential and travel history in Wuhan, <i>n</i> (%)	174 (51.47)

Patients' location of residence, <i>n</i> (%)	99 (29.73%)
Wuhan (the capital of Hubei province)	234 (70.27%)
Other cities of Hubei province	5 (1.48%)
Other provinces	
Close contact with a COVID-19 patient, <i>n</i> (%)	2 (0.59)
Potential COVID-19 exposure, <i>n</i> (%)	17 (5.03)
Diagnosis of COVID-19, <i>n</i> (%)	3 (0.88)

HCQ: hydroxychloroquine; BMI: body mass index; LE: lupus erythematosus; RA: rheumatoid arthritis.

	Exposed to HCQ n=211	Not exposed to HCQ n=127	p
Female, n (%)	179 (84.83)	105 (82.67)	0.647
Age, (years) (mean ± SD)	42.33 ± 14.61	49.39 ± 13.45	<0.001
BMI, kg/m², (mean ± SD)	21.79 ± 3.41	22.15 ± 4.65	0.591
Smoker, n (%)	13 (6.25)	7 (5.60)	1.000
Type, n (%)			
LE	165 (78.2)	66 (51.97)	<0.001
RA	46 (21.80)	61 (48.03)	
Concomitant diseases, n (%)	154 (74.40)	105 (84.68)	0.029
		8	
Medication history, n (%)	188 (89.10)	4 (66.14)	<0.001
Glucocorticoids	11 (5.21)	10 (7.87)	0.357
Methotrexate	8 (3.79)	4 (3.15)	1.000
Cyclosporine	62 (29.38)	28 (22.05)	0.163
Mycophenolate Mofetil	23 (10.90)	11 (8.67)	0.578
Tacrolimus	5 (2.37)	1 (0.79)	0.416
Thalidomide	1 (0.47)	0 (0.00)	1.000
Dapsone	9 (4.27)	12 (9.45)	0.065
Leflunomide	3 (1.42)	0 (0.00)	0.294
Sulfasalazine	5 (2.37)	1 (0.79)	0.416
Iguratimod	1 (0.47)	1 (0.79)	1.000
Tripterygium wilfordii	69 (32.70)	29 (22.83)	0.063
Total glucosides of paeony	4 (1.90)	7 (5.51)	0.110
Biologics			
Recently travelled to Wuhan, n (%)	110 (52.13)	64 (50.40)	0.822
Diagnosis of COVID-19, n (%)	2 (0.96)	1 (0.84)	1.000

Supplementary table 2. Demographic features of study participants, grouped by hydroxychloroquine exposure.

HCQ: hydroxychloroquine; BMI: body mass index; LE: lupus erythematosus; RA: rheumatoid arthritis.